Understanding immune cells after stem cell transplant
Part of Immune system & allergy clinical trials.
This study looks at immune cells in your blood and in tissues affected by chronic graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant. By analyzing samples, researchers hope to better understand this condition and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell or bone marrow transplant from a donor (allogeneic).
- You are 18 years or older, or you are at least 7 years old and weigh 30 kg (about 66 pounds) or more.
- You are willing to provide samples: blood, stool, saliva, and a cheek swab.
- You are not pregnant or nursing (if you can become pregnant).
- You are able to make your own decisions and are not a study team member.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.